-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 24, CDE's official website showed that Qilu Pharmaceutical's "dotegravir sodium tablet" application for listing was accepted
.
Dolutegravir is an anti-AIDS drug, and Qilu is the first in China to declare it this time
.
From : CDE official website
Dolutegravir (DTG) is an anti-AIDS drug developed by GlaxoSmithKline/ViiV, which is an integrase inhibitor
.
In 2015, dolutegravir tablets were approved for marketing in China, and in 2020, GSK submitted a marketing application for dispersible tablets, which is currently under review and approval
.
According to the Insight database, there are currently 3 combination preparations of dolutegravir that have been approved for the market in addition to single drugs worldwide
.
The highest sales is the triple preparation Triumeq, with global sales reaching US$2.
980 billion in 2020; while the sales of dolutegravir single-agent Tivicay in 2020 have declined, reaching US$1.
973 billion, both ranking in 2020.
Ranked among the top 100 pharmaceuticals by annual global sales
.
The global sales of dolutegravir related drugs The
sales trend of dolutegravir over the years
comes from: Insight database (http://db.
dxy.
cn/v5/home/)
At present, except for Qilu, no other company has declared the start-up of dolutegravir.
Telavir generic clinical trials
.
Qilu Pharmaceutical has not only increased its efforts to develop innovative biological drugs recently, but also has maintained its status as the king of traditional generic drugs, and its advancement has been extremely fast
.
The first copy of the CDK4/6 inhibitor palbociclib was extracted by Qilu.
In October last year, it was also the first to submit the application for the marketing of olaparib.
The first, and few other enterprise layouts
.
.
Dolutegravir is an anti-AIDS drug, and Qilu is the first in China to declare it this time
.
From : CDE official website
Dolutegravir (DTG) is an anti-AIDS drug developed by GlaxoSmithKline/ViiV, which is an integrase inhibitor
.
In 2015, dolutegravir tablets were approved for marketing in China, and in 2020, GSK submitted a marketing application for dispersible tablets, which is currently under review and approval
.
According to the Insight database, there are currently 3 combination preparations of dolutegravir that have been approved for the market in addition to single drugs worldwide
.
The highest sales is the triple preparation Triumeq, with global sales reaching US$2.
980 billion in 2020; while the sales of dolutegravir single-agent Tivicay in 2020 have declined, reaching US$1.
973 billion, both ranking in 2020.
Ranked among the top 100 pharmaceuticals by annual global sales
.
The global sales of dolutegravir related drugs The
sales trend of dolutegravir over the years
comes from: Insight database (http://db.
dxy.
cn/v5/home/)
At present, except for Qilu, no other company has declared the start-up of dolutegravir.
Telavir generic clinical trials
.
Qilu Pharmaceutical has not only increased its efforts to develop innovative biological drugs recently, but also has maintained its status as the king of traditional generic drugs, and its advancement has been extremely fast
.
The first copy of the CDK4/6 inhibitor palbociclib was extracted by Qilu.
In October last year, it was also the first to submit the application for the marketing of olaparib.
The first, and few other enterprise layouts
.
